Usana Health Sciences Inc
USNA NYSE· Medicinal Chemicals & Botanical Products
Last close · Oct 27, 2026
$14.07
KIRA · Stoqly’s AI analyst, in plain words
- Usana Health Sciences Inc had $925M of revenue in fiscal 2025, up 8.3% on the year before. Over five years, revenue changed −4.0% a year on average.
- Its operating margin was 4.0%, down 3.7 pts: of every 100 in sales, about 4 is left after running the business.
- Usana Health Sciences Inc made $10.8M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −19.3% a year.
- Free cash flow was $8.5M in fiscal 2025, 0.9% of revenue.
- Usana Health Sciences Inc returned $27.5M to shareholders in fiscal 2025, 323% of free cash flow. The diluted share count fell 3.1%.
Market cap
$260M
P/E
—
Revenue
$925M
Net income
$10.8M
Free cash flow
$8.5M
Operating margin
4.0%
Usana Health Sciences Inc in 30 seconds · fiscal 2025
Are sales growing?
+8.3%
Yes. Sales grew 8.3% last year.
Does it make a profit?
1.2%
A little. It keeps 1.2% of every sale as profit.
Does profit turn into cash?
0.9%
Partly. 0.9% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Usana Health Sciences Inc does
No business description yet.
- Fiscal year ends
- January 3, 2026
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- USANA HEALTH SCIENCES INC
- CIK
- 0000896264
Usana Health Sciences Inc · USNA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.2B | $999M | $921M | $855M | $925M |
| Revenue growth | 4.6% | −15.8% | −7.8% | −7.2% | 8.3% |
| Gross margin | 81.6% | 80.6% | 80.8% | 81.1% | 78.3% |
| Operating margin | 14.3% | 10.8% | 10.1% | 7.8% | 4.0% |
| Net income | $117M | $69.4M | $63.8M | $42.0M | $10.8M |
| Net margin | 9.8% | 6.9% | 6.9% | 4.9% | 1.2% |
| Diluted EPS | $5.73 | $3.59 | $3.30 | $2.19 | $0.58 |
| Cash | |||||
| Cash from operations | $121M | $104M | $70.6M | $61.0M | $22.3M |
| Capital expenditure | $12.8M | $10.4M | $14.5M | $10.1M | $13.8M |
| Free cash flow | $108M | $93.5M | $56.1M | $50.9M | $8.5M |
| FCF margin | 9.1% | 9.4% | 6.1% | 6.0% | 0.9% |
| Share buybacks | $178M | $25.4M | $11.6M | $9.4M | $27.5M |
| Share count change | −4.3% | −5.1% | 0.2% | −0.9% | −3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $240M | $288M | $330M | $182M | $158M |
| Shareholders' equity | $395M | $434M | $497M | $532M | $533M |
| Current ratio | 2.3x | 2.7x | 3.5x | 2.0x | 2.2x |
| Interest coverage | 2,985.8x | 560.5x | 355.2x | 236.0x | 44.5x |
| Returns and quality | |||||
| Return on equity | 27.8% | 16.7% | 13.7% | 8.2% | 2.0% |
| Return on tangible equity | 33.6% | 18.0% | 14.2% | 17.8% | 4.1% |
| Piotroski F-score | 7 | 5 | 5 | 5 | 6 |
| Altman Z'' | 8.5 | 8.8 | 10.2 | 7.4 | 7.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.0M
9 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Usana Health Sciences Inc · USNA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $14.07 a share, the company is worth $260M.
Source: SEC EDGAR XBRL filings (CIK 0000896264). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.